Experienced private and public listed CEOSuccessful fund raising and business development track recordNew CEO available during JPM25 in San Francisco LONDON, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Yaqrit, ...
NEW YORK, NY / ACCESSWIRE / January 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf ...
Just 61% of hospitals surveyed evaluated models for accuracy on their own data, and less than half evaluated the models for ...
Johnson & Johnson MedTech (NYSE: JNJ) announced that it received CE mark approval for its dual-energy ThermoCool SmartTouch ...
Johnson & Johnson stock (NYSE: JNJ) lost about 7% in 2024, underperforming the broader S&P 500 index, which gained 23% for ...
Johnson & Johnson MedTech, a global leader in cardiac arrhythmia treatment, today announced European CE mark approval of the Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter for the treatment of cardiac ...
The temporary pause follows reports of four cases of neurovascular events in the US external evaluation study.
Johnson & Johnson halted the limited rollout of its Varipulse pulsed field ablation system on Jan. 5 to “investigate the root causes of four reported neurovascular events in the U.S. external ...
Johnson & Johnson pauses U.S. Varipulse cases to investigate neurovascular events. The FDA-approved device integrates PFA ...
The FDA and European Medicines Agency (EMA) have granted several key designations to nipocalimab including: U.S. FDA Fast Track designation in hemolytic disease of the fetus and newborn (HDFN) and ...
Mendaera has found a leader with deep medical robotics experience to lead its commercialization push. Eric Davidson has taken ...
Johnson & Johnson has won Food and Drug Administration priority review for its application seeking approval of nipocalimab in certain patients with generalized myasthenia gravis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback